Abstract:Background Iguratimod, a methanesulfonanilide, has obvious anti-inflammatory function and has been developed exclusively in Asia-Pacific countries. As a novel disease-modifying anti-rheumatic drug, iguratimod is effective in the treatment of RA, but some side effects, such as liver damage and gastrointestinal discomforts are the main concerns in clinical application[1]. Currently, iguratimod is practically insoluble in aqueous solvents and only available in oral dosage forms. The low solubility of drugs leads to incomplete absorption and bioavailability, which affects the clinical efficacy and increases the gastrointestinal side effects of drugs[2]. Objectives In order to improve the bioavailability and alleviate the side effect of gastrointestinal reaction, we changed the dosage form of iguratimod to NanoIguratimod-loaded Hydrogel Composite. Methods Iguratimod nanoparticles (NanoIguratimod) were prepared by using the high-gravity anti-solvent precipitation (HGAP) technique, and its properties were tested. The NanoIguratimod-loaded Hydrogel Composite was prepared and the delivery of the payload was demonstrated. In vitro, the biological effects of NanoIguratimod@Hydrogel on fibroblast-like synoviocytes (RA-FLS) were evaluated. In vivo, the pharmacokinetics of oral raw iguratimod or subcutaneous injection of NanoIguratimod@Hydrogel was carried out in the healthy rats. Further, we evaluated the efficacy of NanoIguratimod@Hydrogel in treating collagen-induced arthritis (CIA) rats. Results By the HGAP technique, we acquired the amorphous form NanoIguratimod with an average size of 295nm, which had higher dissolution rates and higher stability. The release of iguratimod from hydrogel composite in PBS was gradual and sustained for up to 48h compared with NanoIguratimod. NanoIguratimod@Hydrogel inhibited the proliferation, migration, and invasion of RA-FLS in a doses dependent manner. The pharmacokinetic parameters showed better bioavailability and longer half-life time with NanoIguratimod@Hydrogel by subcutaneous administration than oral raw iguratimod. Animal experiments confirmed that subcutaneous injection of NanoIguratimod@Hydrogel (10mg/kg every three days) and oral raw iguratimod (10mg/kg daily) showed similar efficacy in decreasing arthritis index score, pathological score, and expression of cytokines (IL-6, TNF-α and IL-1β). Conclusion Overall, our data suggested that NanoIguratimod@Hydrogel provided new administration routes and extended the administration interval, it may serve as a promising drug delivery approach for the treatment of RA. References [1] Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis[J]. Mod Rheumatol., 2007, 17(1):10-16. [2] Zhou T, Ding L, Li X, et al. Determination of iguratimod in rat plasma by high performance liquid chromatography: method and application[J]. Biomed Chromatogr, 2010, 22(3):260-264. Acknowledgement No Disclosure of Interests None declared

In vitro-in vivo assessments of apocynin-hybrid nanoparticle-based gel as an effective nanophytomedicine for treatment of rheumatoid arthritis

Design and Evaluation of Polyherbal Nanogel for The Treatment of Rheumatoid Arthritis

Enhancing collagen based nanoemulgel for effective topical delivery of Aceclofenac and Citronellol oil: Formulation, optimization, in-vitro evaluation, and in-vivo osteoarthritis study with a focus on HMGB-1/RAGE/NF-κB pathway, Klotho, and miR-499a

Synthesis of naringenin loaded lipid based nanocarriers and their in-vivo therapeutic potential in a rheumatoid arthritis model

On-demand drug delivery of triptolide and celastrol by poly(lactic-co-glycolic acid) nanoparticle/triglycerol monostearate-18 hydrogel composite for rheumatoid arthritis treatment

In-Vitro and in-Vivo Evaluation of the Developed Curcumin-Cyclosporine-Loaded Nanoemulgel for the Management of Rheumatoid Arthritis

NOVEL NANO THERAPEUTIC MATERIALS FOR THE EFFECTIVE TREATMENT OF RHEUMATOID ARTHRITIS-RECENT INSIGHTS

A macromolecule infliximab loaded reverse nanomicelles-based transdermal hydrogel: An innovative approach against rheumatoid arthritis

Synergistically engineered nanotransethosomes for co-delivery of methotrexate and baicalin for enhanced transdermal delivery against rheumatoid arthritis: formulation, characterisation and in vivo pharmacodynamic evaluation

Triple-layered platform utilizing electrospun nanofibers and 3D-printed sodium alginate-based hydrogel for effective topical treatment of rheumatoid arthritis

Aminocellulose-grafted-polycaprolactone Coated Gelatin Nanoparticles Alleviate Inflammation in Rheumatoid Arthritis: A Combinational Therapeutic Approach.

In Situ Forming Injectable Hydrogel for Encapsulation of Nanoiguratimod and Sustained Release of Therapeutics

FRI0160 PREPARATION AND PROPERTY OF IGURATIMOD NANOSCALE SUSTAINED-RELEASE SYSTEM

Design, optimization, and evaluation of topical gel of Cardiospermum halicacabum and Ricinus communis L. leaves extract for the treatment of rheumatoid arthritis

Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and In vitro Evaluations

Sinapic acid-pullulan based inflammation responsive nanomicelles for the local treatment of experimental inflammatory arthritis

Locally Injectable Chitosan/β-Glycerophosphate Hydrogel Doped with Triptolide–Human Serum Albumin Nanoparticles for Treating Rheumatoid Arthritis

Anti-inflammation and joint lubrication dual effects of a novel hyaluronic acid/curcumin nanomicelle improve the efficacy of rheumatoid arthritis therapy.

Development, optimization, and characterization of rhein loaded nanoemulgel for treatment of osteoarthritis

The combination of hydrogels and rutin-loaded black phosphorus nanosheets treats rheumatoid arthritis

Formulation and development of topical iron oxide nanoemulgel using Punica granatum extract and in vitro evaluation of anti-inflammatory potential in rheumatoid arthritis